Drug Profile
XR 311
Alternative Names: HN 66000; KSB 311M; KSB 311N; KSB 311P; KSB 311R; PEP04; Project KSB311R; SOT-107; TF CRM 107; Transferrin-CRM 107; TransMID; TransMID 107M; TransMID 107N; TransMID 107P; TransMID 107RLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator GE Healthcare; National Institutes of Health (USA)
- Developer Nycomed; Sosei; Xenova Group
- Class Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS cancer; Glioblastoma; Glioma
Most Recent Events
- 19 Apr 2005 Xenova has licensed XR 311 to PharmaEngine in the Republic of China and in the Republic of South Korea
- 14 Feb 2005 XR 311 has received orphan drug status for glioma in Japan
- 07 Jul 2004 Phase-III clinical trials in Glioblastoma in European Union (Intratumoural)